Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Paola Malaguti"'
Autor:
Alessandra Fabi, Luana Fotia, Federico Giuseppini, Arianna Gaeta, Chiara Falcicchio, Gabriele Giuliani, Antonella Savarese, Emanuela Taraborelli, Valentina Rossi, Paola Malaguti, Diana Giannarelli, Patrizia Pugliese, Francesco Cognetti
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundA virtual reality experience (VRE) could represent a viable non-pharmacological intervention to reduce and better manage the main factors of psychophysical distress related to the diagnosis and treatment of cancer.AimThe “Patient’s Drea
Externí odkaz:
https://doaj.org/article/19f3c2d041044203918a5a9398c63415
Autor:
Alessandra Fabi, Steven Hager, Laura Lourdes, Rebecca Pedersini, Paola Malaguti, Elizabeth M. Gavioli, Renuka Wakade, Pier Adelchi Ruffini, Francesco Sergio, Manuela Leone, Flavio Mantelli, Marcello Allegretti, Anne Blaes
Publikováno v:
Cancer Research. 83:OT1-16
Introduction: Cancer-related fatigue (CRF) is a common symptom in patients with metastatic breast cancer (MBC), who receive taxane-based chemotherapy, and is associated with poor outcomes. Current guidelines recommend regular screening for fatigue fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fac25e12ee04f434a014eae3bae5214c
https://doi.org/10.1158/1538-7445.sabcs22-ot1-16-01
https://doi.org/10.1158/1538-7445.sabcs22-ot1-16-01
Autor:
Paola Papaldo, Francesco Cognetti, Michelangelo Russillo, Paola Malaguti, Diana Giannarelli, Simona Gasparro, Cecilia Nisticò, Gianluigi Ferretti, Francesco Schettini, Grazia Arpino, Alessandra Fabi, Giovanna Catania
Publikováno v:
Future Oncology. 16:1631-1639
Aim: To investigate the toxicity of nab-paclitaxel (wNP)/nonpegylated liposome-encapsulated doxorubicin (wNPLD) combination in HER2-negative metastatic breast cancer (MBC) patients as first-line treatment. Materials & methods: Phase I, single-arm stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1855b9d80f5b5a641080b3eb3e0abb5f
https://doi.org/10.2217/fon-2019-0742
https://doi.org/10.2217/fon-2019-0742
Autor:
Marcella Mottolese, Anna Di Benedetto, Claudio Botti, Alessandra Fabi, Cecilia Nisticò, Patrizia Vici, Cristiana Ercolani, Paola Malaguti, Michelangelo Russillo, Edoardo Pescarmona, Letizia Perracchio, Simonetta Buglioni, Francesca Sperati, Gianluigi Ferretti, Francesco Cognetti, Irene Terrenato
Publikováno v:
Clinical breast cancer. 20(6)
p53 and antiapoptotic B-cell leukemia/lymphoma 2 (BLC2) have been proposed as prognostic markers for early breast cancer (BC), although their relationship with conventional parameters and patient prognosis, as well as their distribution within the mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251194d7ae8900b11175a69ae7b56d90
https://pubmed.ncbi.nlm.nih.gov/32580907
https://pubmed.ncbi.nlm.nih.gov/32580907
Autor:
Nicla La Verde, A.M. D'Ottavio, Francesco Cognetti, Gianfranco Filippelli, Giusy Scandurra, Cecilia Nisticò, Simonetta Stani, Ida Paris, Daniele Alesini, Grazia Arpino, Marianna Giampaglia, Daniele Santini, Alberto Zambelli, Roberta Caputo, Luca Moscetti, Giovanna Catania, Diana Giannarelli, Michele Caruso, Rosalba Rossello, Paola Malaguti, Katia Cannita, Alessandra Fabi, Vita Leonardi, Filippo Montemurro, Michelangelo Russillo, E. Valle, Mariangela Ciccarese, Gianluigi Ferretti, A. Fabbri, Luisa Carbognin
Publikováno v:
The Breast. 41:137-143
Background We reported the results of an Italian large retrospective analysis that evaluated the effectiveness and safety of T-DM1 in ‘field-practice’ breast cancer patients. We performed a sub-analysis to investigate the clinical activity of T-D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa30bbb305dae5fd40fda85b5132439a
https://doi.org/10.1016/j.breast.2018.07.004
https://doi.org/10.1016/j.breast.2018.07.004
Autor:
Italia Falcone, Francesco Cognetti, Paola Malaguti, Fabiana Conciatori, Chiara Bazzichetto, Ludovica Ciuffreda, Luisa Carbognin, Michele Milella, Gianluigi Ferretti, Emilio Bria
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 8419, p 8419 (2020)
International Journal of Molecular Sciences
International Journal of Molecular Sciences
Breast cancer was one of the first malignancies to benefit from targeted therapy, i.e., treatments directed against specific markers. Inhibitors against HER2 are a significant example and they improved the life expectancy of a large cohort of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d038936e0b60d36c7cd102322612f02
https://doi.org/10.3390/ijms21228419
https://doi.org/10.3390/ijms21228419
Autor:
Antonello Vidiri, Simona Gasparro, Paola Malaguti, Francesco Cognetti, Alessandra Fabi, Giovanna Catania
Publikováno v:
Oncology. 94
Background: Brain metastases develop in approximately 10–25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis. Case Report: We report the case of a 40-year-old woman with MBC and associated lung, bone, l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bde17fdc57c86f84a2514266ee48e660
https://pubmed.ncbi.nlm.nih.gov/30041177
https://pubmed.ncbi.nlm.nih.gov/30041177
Publikováno v:
Journal of Experimental & Clinical Cancer Research : CR
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ca17a337b504a2fa8d01997ba5f3b7c
http://europepmc.org/articles/PMC4928292
http://europepmc.org/articles/PMC4928292
Autor:
Antonio De Blasi, Paola Malaguti, Antonella Viterbo, Cristiano Ialongo, Paolo Marchetti, Giovanna Gentile, Luca Marchetti, Luana Lionetto, Ida Paris, Alfonso Lostia, Maurizio Simmaco
Publikováno v:
Therapeutic Drug Monitoring. 31:482-488
5-Fluorouracil (5-FU) is a major chemotherapy drug used for the treatment of tumors. It is catabolized mainly by dihydropyrimidine dehydrogenase, and patients with a complete or partial deficiency of dihydropyrimidine dehydrogenase activity are at ri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f020f869ffa151af1b03e66e9f5a007c
https://doi.org/10.1097/ftd.0b013e3181ae4516
https://doi.org/10.1097/ftd.0b013e3181ae4516